• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

四种程序性死亡受体配体1(PD-L1)免疫组化检测方法在食管鳞状细胞癌(ESCC)中的评估一致性

Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC).

作者信息

Wang Xinran, He Jiankun, Li Jinze, Wu Chun, Yue Meng, Niu Shuyao, Jia Ying, Jia Zhanli, Cai Lijing, Liu Yueping

机构信息

Department of Pathology, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.

出版信息

J Cancer Res Clin Oncol. 2024 Jan 28;150(2):43. doi: 10.1007/s00432-023-05595-0.

DOI:10.1007/s00432-023-05595-0
PMID:38280970
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10821831/
Abstract

OBJECTIVE

Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordance studies between PD-L1 assays are needed. We undertook comparisons of PD-L1 assays (DAKO22C3, Ventana SP263, Ventana SP142, E1L3N) among observers in esophageal squamous cell carcinoma (ESCC) to provide information on the analytical and clinical comparability of four PD-L1 IHC assays.

METHODS

Paraffin embedded samples of 50 cases of esophageal squamous cell carcinoma were obtained, satined with all four PD-L1 assays. PD-L1 was evaluated by 68 pathologists from 19 different hospitals. PD-L1 expression was assessed for combined positive score (CPS).

RESULTS

The expression sensitivity of SP263 was the highest in ESCC, followed by 22C3, E1L3N and SP142. Taking CPS 10 as the critical value, inter-observer concordance for CPS scores among 68 physicians was assessed for the 22C3, SP263, SP142, and E1L3N assays, yielding values of 0.777, 0.790, 0.758, and 0.782, respectively. In the comparison between assays, the overall CPS scores concordance rates between 22C3 and SP263, SP142, and E1L3N were 0.896, 0.833, and 0.853, respectively. 22C3 and SP263 have high concordance, with OPA of 0.896, while E1L3N and SP142 have the highest concordance, with OPA of 0.908.

CONCLUSION

In ESCC, the concordance of PD-L1 evaluation among observers is good, and the immune cell score is still an important factor affecting the concordance of interpretation among observers. Cases near the specific threshold are still the difficult problem of interpretation. SP263 had the highest CPS score of the four assays. SP263 cannot identify all 22C3 positive cases, but had good concordance with 22C3.E1L3N and SP142 showed high concordance.

摘要

目的

鉴于程序性死亡配体1(PD-L1)检测在现实世界中的局限性,需要对PD-L1检测方法之间进行一致性研究。我们对食管鳞状细胞癌(ESCC)观察者中的PD-L1检测方法(DAKO22C3、Ventana SP263、Ventana SP142、E1L3N)进行了比较,以提供关于四种PD-L1免疫组化检测方法的分析和临床可比性的信息。

方法

获取50例食管鳞状细胞癌的石蜡包埋样本,用所有四种PD-L1检测方法进行检测。由来自19家不同医院的68名病理学家对PD-L1进行评估。评估PD-L1表达的综合阳性评分(CPS)。

结果

SP263在ESCC中的表达敏感性最高,其次是22C3、E1L3N和SP142。以CPS 10为临界值,对68名医生中22C3、SP263、SP142和E1L3N检测方法的CPS评分观察者间一致性进行评估,分别得出0.777、0.790、0.758和0.782的值。在检测方法之间的比较中,22C3与SP263、SP142和E1L3N之间的总体CPS评分一致性率分别为0.896、0.833和0.853。22C3和SP263具有高度一致性,重叠百分比一致性(OPA)为0.896,而E1L3N和SP142具有最高的一致性,OPA为0.908。

结论

在ESCC中,观察者间PD-L1评估的一致性良好,免疫细胞评分仍是影响观察者间解读一致性的重要因素。接近特定阈值的病例仍是解读的难题。SP263是四种检测方法中CPS评分最高的。SP263不能识别所有22C3阳性病例,但与22C3具有良好的一致性。E1L3N和SP142显示出高度一致性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ec/11793616/314590997766/432_2023_5595_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ec/11793616/183b4e2e1338/432_2023_5595_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ec/11793616/d18685da3b6f/432_2023_5595_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ec/11793616/314590997766/432_2023_5595_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ec/11793616/183b4e2e1338/432_2023_5595_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ec/11793616/d18685da3b6f/432_2023_5595_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ec/11793616/314590997766/432_2023_5595_Fig3_HTML.jpg

相似文献

1
Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC).四种程序性死亡受体配体1(PD-L1)免疫组化检测方法在食管鳞状细胞癌(ESCC)中的评估一致性
J Cancer Res Clin Oncol. 2024 Jan 28;150(2):43. doi: 10.1007/s00432-023-05595-0.
2
PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays.PD-L1 表达在非小细胞肺癌中的应用:使用 E1L3N 克隆与 22C3 和 SP263 检测试剂盒比较评估实验室开发检测试剂盒的诊断准确性。
Hum Pathol. 2019 Aug;90:54-59. doi: 10.1016/j.humpath.2019.05.003. Epub 2019 May 21.
3
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌中 PD-L1 免疫组织化学检测方法的比较。
J Natl Cancer Inst. 2021 Nov 29;113(12):1733-1743. doi: 10.1093/jnci/djab108.
4
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.一项非小细胞肺癌中 PD-L1 表达的前瞻性、多机构、基于病理学家的 4 种免疫组化检测评估。
JAMA Oncol. 2017 Aug 1;3(8):1051-1058. doi: 10.1001/jamaoncol.2017.0013.
5
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.四种市售的、已验证的程序性死亡配体-1 检测方法在尿路上皮癌中的一致性。
Diagn Pathol. 2019 Sep 2;14(1):99. doi: 10.1186/s13000-019-0873-6.
6
PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.使用SP263、SP142和22C3抗体检测膀胱尿路上皮癌中PD-L1的免疫组化表达:一项比较研究。
Ann Diagn Pathol. 2024 Apr;69:152267. doi: 10.1016/j.anndiagpath.2024.152267. Epub 2024 Jan 20.
7
PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.转移性三阴性乳腺癌中的 PD-L1 检测:CE-IVD 检测 CPS 和 IC 评分的观察者间和平台间可重复性。
Hum Pathol. 2024 Feb;144:22-27. doi: 10.1016/j.humpath.2024.01.008. Epub 2024 Jan 24.
8
SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.SP142 PD-L1 评分在三阴性乳腺癌中显示出较高的观察者间和观察者内一致性,但与其他 PD-L1 克隆 SP263 和 22C3 的总一致性百分比较低。
Am J Surg Pathol. 2021 Aug 1;45(8):1108-1117. doi: 10.1097/PAS.0000000000001701.
9
Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.头颈部鳞状细胞癌、尿路上皮癌和乳腺癌中程序性死亡配体 1 评分的观察者间和观察者内一致性。
Histopathology. 2020 Jan;76(2):191-200. doi: 10.1111/his.13946. Epub 2019 Sep 9.
10
Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection.三种经过验证的 PD-L1 免疫组织化学检测方法在膀胱癌中的比较:可互换性和与患者选择相关的问题。
Front Immunol. 2022 Jul 27;13:954910. doi: 10.3389/fimmu.2022.954910. eCollection 2022.

引用本文的文献

1
Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift.免疫检查点抑制剂在食管鳞状细胞癌一线治疗中的应用:重大转变的综述
World J Gastrointest Oncol. 2025 Jun 15;17(6):106707. doi: 10.4251/wjgo.v17.i6.106707.
2
Augmented reality microscopy to bridge trust between AI and pathologists.增强现实显微镜技术,架起人工智能与病理学家之间的信任桥梁。
NPJ Precis Oncol. 2025 May 12;9(1):139. doi: 10.1038/s41698-025-00899-5.
3
Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.

本文引用的文献

1
How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies.人工智能模型如何辅助乳腺癌中PD-L1表达评分:多机构环形研究结果
NPJ Breast Cancer. 2021 May 26;7(1):61. doi: 10.1038/s41523-021-00268-y.
2
Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study.晚期非小细胞肺癌细胞学涂片上程序性死亡配体1(PD-L1)肿瘤比例评分(TPS)的可靠性:一项前瞻性验证研究
Ther Adv Med Oncol. 2020 Nov 30;12:1758835920954802. doi: 10.1177/1758835920954802. eCollection 2020.
3
替雷利珠单抗治疗晚期或转移性食管鳞状细胞癌的突变与生存分析:来自随机、III期、RATIONALE-302试验的生物标志物分析
J Clin Oncol. 2025 Jun;43(16):1898-1909. doi: 10.1200/JCO-24-01818. Epub 2025 Apr 3.
PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation.
PD-L1 免疫组化检测在非小细胞肺癌中的应用:解析染色一致性和解读差异。
Virchows Arch. 2021 May;478(5):827-839. doi: 10.1007/s00428-020-02976-5. Epub 2020 Dec 4.
4
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.帕博利珠单抗对比化疗用于晚期食管癌的随机 III 期 KEYNOTE-181 研究。
J Clin Oncol. 2020 Dec 10;38(35):4138-4148. doi: 10.1200/JCO.20.01888. Epub 2020 Oct 7.
5
Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.前瞻性多机构评估病理学家评估 PD-L1 检测在三阴性乳腺癌患者选择中的应用。
Mod Pathol. 2020 Sep;33(9):1746-1752. doi: 10.1038/s41379-020-0544-x. Epub 2020 Apr 16.
6
Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists.非小细胞肺癌中PD-L1生物标志物的观察者间可重复性:27位病理学家的多机构研究
J Pathol Transl Med. 2019 Nov;53(6):347-353. doi: 10.4132/jptm.2019.09.29. Epub 2019 Oct 28.
7
Digital immunohistochemistry implementation, training and validation: experience and technical notes from a large clinical laboratory.数字免疫组织化学的实施、培训和验证:来自一个大型临床实验室的经验和技术注释。
J Clin Pathol. 2019 May;72(5):373-378. doi: 10.1136/jclinpath-2018-205628. Epub 2019 Feb 14.
8
Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.使用VENTANA SP263检测法检测肿瘤块内及肿瘤块之间肿瘤和免疫细胞程序性细胞死亡配体-1表达的一致性。
Diagn Pathol. 2018 Jul 24;13(1):47. doi: 10.1186/s13000-018-0725-9.
9
Molecular landscape of esophageal cancer: implications for early detection and personalized therapy.食管癌的分子图谱:对早期检测和个体化治疗的启示。
Ann N Y Acad Sci. 2018 Dec;1434(1):342-359. doi: 10.1111/nyas.13876. Epub 2018 Jun 19.
10
PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.PD-L1 检测试剂 22C3 和 SP263 在考虑临床相关截断值时在非小细胞肺癌中不可互换:不同培训的病理学家进行的克隆间评估。
Am J Surg Pathol. 2018 Oct;42(10):1384-1389. doi: 10.1097/PAS.0000000000001105.